[1P-0968] Semaphorin 3F inhibits breast tumor angiogenesis and metastasis

〇Hironao Nakayama^1,2,3, Akari Murakami^3,4, Hisayo Nishida-Fukuda^3,4, Yoshiaki Kamei⁴, Yasutsugu Takada⁴, Shigeki Higashiyama^2,3 (1.Dept. of Med. Sci. & Tech., Hiroshima Int. Univ., 2.Div. of Cell Growth & Tumor Reg., PROS, Ehime Univ., 3.Dept. of Biochem. & Mol. Gene., Grad. Sch. of Med., Ehime Univ., 4.Dept. of Surgery, Grad. Sch. of Med., Ehime Univ.)

ConBio2017

[1P-0969] Nutrient concentration changes regulate the expression of short H-ras isoform in high grade cancer cells

〇Naoki Tamura^1,2, Sakura Ikeda¹, Marco Marques Candeias¹ (1.MaRCU, Grad. Sch. of Med, Univ. of Kyoto, 2.Kyoto University Hospital)

ConBio2017

[1P-0970] Anticancer properties of Propofol correlate with Body Mass Index

〇Patraphol Panitvorapume¹, Hiroyasu Iso², Shinnosuke Shiono³, Shocarl Shibata⁴ (1.Medical School, Osaka Univ., 2.Dept. of Public Health, Osaka Univ., 3.Dept. of Anesthesiology, National Defense Medical College, 4.Dept. of Anesthesiology, Osaka Univ.)

ConBio2017

[1P-0971] Involvement of the regulatory systems of glutathione synthesis in invasion of human sarcoma

〇Ryosuke Kusumi¹, Haruka Suzuki¹, Kunisige Onuma², Mitsuhiko Osaki², Shiro Bannai¹, Futoshi Okada², Hideyo Sato¹ (1.Niigata Univ., Facul. of Med., Sch. of Health Sci, 2.Sch. of Life Sci., Facul. of Med., Tottori Univ. )

ConBio2017

[1P-0972] EphA2 S897 phosphorylation regulated by its tyrosine kinase activity

〇Yuho Hamaoka¹, Manabu Negishi^1,2, Hironori Katoh^1,2 (1.Lab. of Mol. Neurobiol., Grad.Sch. of Pharmaceutical Sciences, Kyoto Univ., 2.Lab. of Mol. Neurobiol., Grad.Sch. of Biostudies, Kyoto Univ.)

ConBio2017

[1P-0973] Transcription factor NRF3 (NFE2L3) promotes tumorigenesis through 20S proteasome activation

〇Tsuyoshi Waku¹, Misaki Koji², Nanami Kamada², Chika Tatsumi², Atsushi Hatanaka², Akira Kobayashi^1,2 (1.Fac. of Life and Med. Sci., Doshisha Univ., 2.Grad. Sch. of Life and Med. Sci., Doshisha Univ.)

ConBio2017

[1P-0974] Testicular germ cell tumor model based on DDX1 overexpression and PTPN23 deficiency

〇Narumi Ikeda^1,2, Kiyoko Tanaka¹, Takahiko Hara^1,2 (1.Stem Cell Project, Tokyo Metropol. Inst. Med. Sci., 2.Grad. Sch., Tokyo Med. Dent. Univ.)

ConBio2017

[1P-0975] Functional evaluation of a novel recombinant fusion protein drug targeting HIF-active cancers

〇Takehiro Ito¹, Tetsuya Kadonosono¹, Takahiro Kuchimaru¹, Shinae Kondoh¹ (1.Dept. Life Sci. & Tech, Tokyo Tech.)

ConBio2017

[1P-0976] A receptor-type protein tyrosine phosphatase PTPRK inhibits CD133-dependent tumor growth and drug-resistance of colon cancer cells via dephosphorylation of CD133.

〇Yusuke Mori^1,2, Osamu Shimozato^1,3, Kyosuke Uchiumi^1,2, Meijie Sang¹, Takahiro Inoue^2,4, Toshinori Ozaki^1,2 (1.Chiba Cancer Ctr. Res. Inst. Lab. of DNA Damage signaling, 2.Dept. of Mol. Biol. and Oncol., Chiba Univ. Sch. of Med., 3.Chiba Cancer Ctr. Res. Inst. Lab. of Oncogenomics, 4.Chiba Cancer Ctr. Res. Inst. Lab. of DNA Cancer Genetics)

ConBio2017

[1P-0977] Neural Crest Gene Screening Identifies ZIC5 as a Target for Drug Resistance of Cancer Cells

〇Reiko Satow^1,2, Miku Endo¹, Chiaki Kato¹, Shota Inagaki¹, Kiyoko Fukami^1,2 (1.Lab. of Genome and Biosignals, Tokyo Univ. of Pharm. and Life Sci., 2.AMED-CREST, AMED)

ConBio2017